Nolvadex (Tamoxifen)

Tamoxifen is a prodrug that is metabolized by CYP2D6 and CYP3A4 into active metabolites endoxifen and 4-hydroxytamoxifen. These metabolites competitively bind estrogen receptors (primarily ER-alpha) in breast tissue, blocking estradiol from activating those receptors. In the hypothalamus and pituitary, this estrogen blockade removes negative feedback, causing a significant increase in gonadotropin-releasing hormone (GnRH) pulsatility, which stimulates LH and FSH release. LH then drives Leydig cells in the testes to produce testosterone. Tamoxifen does NOT reduce circulating estrogen levels — it only blocks estrogen action at receptor sites.

Oral bioavailability is approximately 100%. Peak plasma concentration reached in 4-7 hours. Highly protein-bound (>99%). Extensively metabolized in the liver via CYP2D6 (primary) and CYP3A4. Active metabolite endoxifen has 30-100x greater affinity for estrogen receptors than tamoxifen itself. Terminal elimination half-life of the parent compound is 5-7 days; active metabolites persist 10-14 days. Reaches steady state in approximately 4-8 weeks at constant dosing, but PCT doses are short-term and front-loaded.

• ✓Restores natural testosterone production by increasing LH and FSH
• ✓Prevents and can reverse gynecomastia by blocking estrogen at breast tissue
• ✓Maintains gains post-cycle by preventing the catabolic crash of low testosterone
• ✓Weak estrogenic activity in bone preserves bone mineral density
• ✓Improves lipid profile via estrogenic action in the liver (raises HDL)
• ✓Well-studied with decades of clinical data on safety and efficacy
• ✓Can be used both on-cycle for gyno prevention and post-cycle for PCT

• ⚠Visual disturbances (rare but notable — blurred vision, light sensitivity)
• ⚠Hot flashes and night sweats
• ⚠Emotional mood swings, irritability, and brain fog during PCT
• ⚠Decreased libido during initial PCT phase before testosterone recovers
• ⚠Potential reduction in IGF-1 levels by approximately 20-25%
• ⚠Blood clot risk slightly elevated (DVT/PE — rare at PCT doses and durations)
• ⚠Joint stiffness in some users
• ⚠Nausea at higher doses, especially the first few days at 40mg
• ⚠CYP2D6 poor metabolizers may have reduced efficacy (genetic variation)

Contraindications

• 🚫Active or history of blood clots (DVT, pulmonary embolism)
• 🚫Known CYP2D6 poor metabolizer status (consider switching to Clomid or enclomiphene)
• 🚫Concurrent use of strong CYP2D6 inhibitors (SSRIs like paroxetine, fluoxetine — these dramatically reduce endoxifen levels)
• 🚫Pre-existing vision disorders or cataracts
• 🚫Liver disease or significantly elevated liver enzymes
• 🚫Women who are pregnant or breastfeeding
• 🚫Hypersensitivity to tamoxifen citrate

Standard PCT after testosterone-only cycle: Start Nolvadex 2 weeks after last injection of long-ester (Cypionate/Enanthate) or 3 days after last short-ester (Propionate) injection. Run 40/40/20/20 over 4 weeks. After 19-nors (Nandrolone/Trenbolone): Wait 3-4 weeks after last Deca injection or 2 weeks after NPP. Consider adding HCG 1000-1500 IU EOD for 2 weeks BEFORE starting Nolvadex to prime the testes. After harsh suppressive cycles (high-dose multi-compound): HCG bridge 2-3 weeks, then Nolvadex 40/40/20/20/10/10 for 6 weeks. Always confirm recovery with bloodwork 4-6 weeks after PCT completion.

• 1.Do NOT combine with Clomid unless absolutely necessary — both are SERMs competing for the same receptors and the side effect profile stacks without proportional benefit
• 2.Avoid grapefruit juice — it inhibits CYP3A4 and can alter tamoxifen metabolism
• 3.If you experience any vision changes (blurriness, seeing spots), discontinue immediately and consult a doctor
• 4.SSRIs (especially paroxetine and fluoxetine) dramatically reduce Nolvadex efficacy by inhibiting CYP2D6 — use alternative antidepressants if needed during PCT
• 5.Store at room temperature away from light and moisture
• 6.Take at the same time each day for consistent blood levels
• 7.Some users report that Nolvadex makes them more emotional/moody than Clomid — this is individual, try both over separate cycles to see which you tolerate better
• 8.HCG before PCT (not during) produces much better outcomes — priming Leydig cells before asking LH to stimulate them makes recovery faster

1. [1]Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609-1618.
2. [2]Klotz L. Pharmacokinetics and drug metabolism of tamoxifen. Anti-Cancer Drugs. 1993;4 Suppl 2:3-8.
3. [3]Devoto E et al. Clomiphene and tamoxifen in the treatment of male hypogonadism. Fertil Steril. 2009.
4. [4]Veldhuis JD. Neuroendocrine control of pulsatile LH release in the human. J Neuroendocrinol. 2000.